nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

22.08.2017 | Retinal Disorders

Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting

verfasst von: S. Vo Kim, F. Fajnkuchen, V. Sarda, L. Qu-Knafo, B. Bodaghi, A. Giocanti-Aurégan

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).

Methods

A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP <21 mmHg (group 2) and ≥21 mmHg (group 3). Rate and several risk factors of IOP elevation were assessed and compared between the three groups.

Results

IOP elevation occurred in ten eyes (7.1%). IOP was <21 mmHg in six eyes and ≥21 mmHg in four eyes. Statistically significant associations were found between IOP elevation and the number of injections, and HbA1c level. Two patients required local hypotonic treatment.

Conclusions

In a real-life setting, we confirmed in eyes with center-involved DME without prior glaucoma or IOP elevation that repeated anti-VEGF IVI may increase the risk of sustained IOP elevation in about 7% of eyes.

Romero-Aroca P (2011) Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes 2:98–104. https://doi.org/10.4239/wjd.v2.i6.98 CrossRefPubMedPubMedCentral

Klein R, Klein BE, Moss SE, Cruickshanks KJ (1995) The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102:7–16CrossRefPubMed

Yau JWY, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564. https://doi.org/10.2337/dc11-1909 CrossRefPubMedPubMedCentral

Delcourt C, Massin P, Rosilio M (2009) Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population. Diabetes Metab 35:431–438. https://doi.org/10.1016/j.diabet.2009.06.002 CrossRefPubMed

Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359. https://doi.org/10.1016/j.ophtha.2016.02.022 CrossRefPubMedPubMedCentral

Heier JS, Korobelnik J-F, Brown DM et al (2016) Intravitreal Aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376–2385. https://doi.org/10.1016/j.ophtha.2016.07.032 CrossRefPubMed

Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405. https://doi.org/10.2337/dc10-0493 CrossRefPubMedPubMedCentral

Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022. https://doi.org/10.1016/j.ophtha.2013.02.034 CrossRefPubMed

Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039 CrossRefPubMed

10.

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203. https://doi.org/10.1056/NEJMoa1414264 CrossRef

11.

Boyer DS, Nguyen QD, Brown DM et al (2015) Outcomes with as-needed Ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 122:2504–2513.e1. https://doi.org/10.1016/j.ophtha.2015.08.006 CrossRefPubMed

12.

Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625. https://doi.org/10.1016/j.ophtha.2011.01.031 CrossRefPubMed

13.

Qu-Knafo L, Fajnkuchen F, Sarda V et al (2016) French practice patterns in the management of diabetic macular edema. J Fr Ophtalmol 39:521–526. https://doi.org/10.1016/j.jfo.2016.02.005 CrossRefPubMed

14.

Xu Y, Tan CS (2016) Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. https://doi.org/10.1007/s10792-016-0241-4

15.

van der Reis MI, La Heij EC, De Jong-Hesse Y et al (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina Phila Pa 31:1449–1469. https://doi.org/10.1097/IAE.0b013e3182278ab4 CrossRef

16.

Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95–113. https://doi.org/10.1016/j.survophthal.2010.08.006 CrossRefPubMed

17.

Ladas ID, Karagiannis DA, Rouvas AA et al (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina Phila Pa 29:313–318. https://doi.org/10.1097/IAE.0b013e31819a5f98 CrossRef

18.

Baek SU, Park IW, Suh W (2016) Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol 35:310–314. https://doi.org/10.3109/15569527.2015.1124886 CrossRefPubMed

19.

Nariani A, Williams B, Hariprasad SM (2016) Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol 64:643–647. https://doi.org/10.4103/0301-4738.194329 CrossRefPubMedPubMedCentral

20.

Beato J, Pedrosa AC, Pinheiro-Costa J et al (2016) Long-term effect of anti-VEGF agents on intraocular pressure in age-related macular degeneration. Ophthalmic Res 56:30–34. https://doi.org/10.1159/000444395 CrossRefPubMed

21.

Agard E, Elchehab H, Ract-Madoux G et al (2015) Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol J Can Ophtalmol 50:127–131. https://doi.org/10.1016/j.jcjo.2014.11.004 CrossRef

22.

Yannuzzi NA, Patel SN, Bhavsar KV et al (2014) Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 158:319–327.e2. https://doi.org/10.1016/j.ajo.2014.04.029 CrossRefPubMed

23.

Kim YJ, Sung KR, Lee KS et al (2014) Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol 157:1266–1271.e1. https://doi.org/10.1016/j.ajo.2014.02.035 CrossRefPubMed

24.

Bakri SJ, Moshfeghi DM, Francom S et al (2014) Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 121:1102–1108. https://doi.org/10.1016/j.ophtha.2013.11.029 CrossRefPubMed

25.

Yu AL, Seidensticker F, Schaumberger M et al (2014) Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab. Clin Ophthalmol Auckl NZ 8:743–747. https://doi.org/10.2147/OPTH.S58410 CrossRef

26.

Mathalone N, Arodi-Golan A, Sar S et al (2012) Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 250:1435–1440. https://doi.org/10.1007/s00417-012-1981-0 CrossRef

27.

Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. https://doi.org/10.1136/bjo.2010.180729 CrossRefPubMed

28.

Song BJ, Aiello LP, Pasquale LR (2016) Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep 16:124. https://doi.org/10.1007/s11892-016-0815-6 CrossRefPubMedPubMedCentral

29.

Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597. https://doi.org/10.1001/jamaophthalmol.2015.186 CrossRefPubMedPubMedCentral

30.

Zhou Y, Zhou M, Xia S et al (2016) Sustained elevation of intraocular pressure associated with Intravitreal Administration of Anti-Vascular Endothelial Growth Factor: a systematic review and meta-analysis. Sci Rep 6:39301. https://doi.org/10.1038/srep39301 CrossRefPubMedPubMedCentral

31.

Kiddee W, Montriwet M (2015) Intraocular pressure changes in non-glaucomatous patients receiving Intravitreal anti-vascular endothelial growth factor agents. PLoS One 10:e0137833. https://doi.org/10.1371/journal.pone.0137833 CrossRefPubMedPubMedCentral

32.

Hoang QV, Mendonca LS, Della Torre KE et al (2012) Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119:321–326. https://doi.org/10.1016/j.ophtha.2011.08.011 CrossRefPubMed

33.

Al-Abdullah AA, Nowilaty SR, Asghar N et al (2015) Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema. Retina Phila Pa 35:440–448. https://doi.org/10.1097/IAE.0000000000000371 CrossRef

34.

Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006 CrossRefPubMed

35.

Bressler SB, Glassman AR, Almukhtar T et al (2016) Five-year outcomes of Ranibizumab with prompt or deferred laser versus laser or Triamcinolone plus deferred Ranibizumab for diabetic macular edema. Am J Ophthalmol 164:57–68. https://doi.org/10.1016/j.ajo.2015.12.025 CrossRefPubMedPubMedCentral

36.

Pasquale LR, Kang JH, Manson JE et al (2006) Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 113:1081–1086. https://doi.org/10.1016/j.ophtha.2006.01.066 CrossRefPubMed

37.

Zhao D, Cho J, Kim MH et al (2015) Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology 122:72–78. https://doi.org/10.1016/j.ophtha.2014.07.051 CrossRefPubMed

38.

Chopra V, Varma R, Francis BA et al (2008) Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino eye study. Ophthalmology 115:227–232.e1. https://doi.org/10.1016/j.ophtha.2007.04.049 CrossRefPubMed

39.

de Voogd S, Ikram MK, Wolfs RCW et al (2006) Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam study. Ophthalmology 113:1827–1831. https://doi.org/10.1016/j.ophtha.2006.03.063 CrossRefPubMed

40.

David R, Zangwill L, Briscoe D et al (1992) Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol 76:280–283CrossRefPubMedPubMedCentral

41.

Syam PP, Mavrikakis I, Liu C (2005) Importance of early morning intraocular pressure recording for measurement of diurnal variation of intraocular pressure. Br J Ophthalmol 89:926–927. https://doi.org/10.1136/bjo.2004.052787 CrossRefPubMedPubMedCentral

42.

Kahook MY, Ammar DA (2010) In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 19:437–441. https://doi.org/10.1097/IJG.0b013e3181ca74de CrossRefPubMed

43.

Liu L, Ammar DA, Ross LA et al (2011) Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 52:1023–1034. https://doi.org/10.1167/iovs.10-6431 CrossRefPubMedPubMedCentral

44.

Ricca AM, Morshedi RG, Wirostko BM (2015) High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 31:2–10. https://doi.org/10.1089/jop.2014.0062 CrossRef

Titel: Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting
verfasst von: S. Vo Kim
F. Fajnkuchen
V. Sarda
L. Qu-Knafo
B. Bodaghi
A. Giocanti-Aurégan
Publikationsdatum: 22.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3782-y

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Location and pressure dependent transmission of human and porcine sclera: an anterior to posterior examination

Sebaceous gland carcinoma of the ocular adnexa – variability in clinical and histological appearance with analysis of immunohistochemical staining patterns

Quantitative analysis of photoreceptor layer reflectivity on en-face optical coherence tomography as an estimator of cone density

Optical coherence tomography angiography in acute arteritic and non-arteritic anterior ischemic optic neuropathy

Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion

The interaction of pupil response with the vergence system

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde